Director Terrie Curran filed a Form 4 with the SEC on August 24, 2026, disclosing the exercise of a stock option and the same-day sale of shares in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) on August 20, 2026.

Key Highlights

  • Option exercise: Curran exercised a stock option for 1,072 shares of common stock at an exercise price of $7.51 per share on August 20, 2026.
  • Shares sold: 1,072 shares were sold on August 20, 2026, at a weighted average price of $26.0376, with individual sales ranging from $26.00 to $26.2228.
  • Remaining ownership: Following the transactions, Curran directly beneficially owned 23,526 shares of common stock.
  • Remaining options: 11,148 stock options with a $7.51 exercise price and an expiration date of May 31, 2033, remain held directly.
  • Option status: According to the filing, the exercised option was fully vested as of the transaction date.

Option Exercise and Same-Day Sale by Arcutis Biotherapeutics Director Terrie Curran

According to the Form 4 filed on August 24, 2026, Terrie Curran, a director of Arcutis Biotherapeutics, Inc., reported two transactions dated August 20, 2026. Curran exercised a stock option (transaction code M) covering 1,072 shares of common stock at a conversion price of $7.51 per share. The filing noted that the option was fully vested at the time of exercise and had an expiration date of May 31, 2033.

On the same date, Curran disposed of 1,072 shares of common stock through a sale (transaction code S) at a weighted average price of $26.0376 per share. The filing stated that the shares were sold in multiple transactions at prices ranging from $26.00 to $26.2228, inclusive, and that Curran undertakes to provide full information on the number of shares sold at each price upon request from the SEC staff, the issuer, or a security holder.

After both transactions, the filing reported Curran's direct beneficial ownership of common stock at 23,526 shares. In Table II, the filing disclosed that 11,148 stock options with a $7.51 exercise price remain directly held, with an expiration date of May 31, 2033. The form was signed by Latha Vairavan as attorney-in-fact for Terrie Curran on August 24, 2026. The filing noted that the underlying option shares vest 100% on the first anniversary of May 31, 2023, subject to continuous service as a non-employee director.

What Was Disclosed

The filing disclosed a same-day option exercise and sale of 1,072 shares by Arcutis Biotherapeutics director Terrie Curran on August 20, 2026, resulting in direct beneficial ownership of 23,526 common shares and 11,148 remaining stock options.